Articles from Foundation for the National Institutes of Health

The Foundation for the National Institutes of Health (FNIH) will award the inaugural Montrone-Seigel Prize in Biomedical Sciences to molecular biologist David Liu, PhD. He and his team have developed innovative gene editing technologies that are being used worldwide to study and treat genetic diseases, including in at least 23 clinical trials targeting cancer, blood diseases, metabolic disorders and other conditions.

The Foundation for the National Institutes of Health (FNIH) will award the 2025 Paul-Gallin Trailblazer Prize for Physician-Scientists to Matthew Greenblatt, MD, PhD, of Weill Cornell Medicine and NewYork-Presbyterian. Dr. Greenblatt and his team have discovered three distinct stem cell types involved in bone formation, revealing potential therapeutic targets for osteoporosis, rare genetic disorders of the bone, and cancer metastases.

The Foundation for the National Institutes of Health (FNIH) is managing a new program to advance innovative laboratory technologies that model human biology, enabling faster, less expensive testing.

The Foundation for the National Institutes of Health (FNIH) will award the 2025 Charles A. Sanders, MD, Partnership Award to the National Institutes of Health’s (NIH) National Center for Advancing Translational Sciences (NCATS), Alexandria Real Estate Equities, Inc./Alexandria Venture Investments and the Goldenberg Family Foundation. The Partnership Award recognizes persons or organizations that have made significant contributions to the FNIH’s work in support of the mission of the NIH.

The Foundation for the National Institutes of Health (FNIH) announces the establishment of an endowment for a prize to be renamed the Paul-Gallin Trailblazer Prize for Physician-Scientists, an annual award given to a physician whose research has the potential to transform patient care.

The Foundation for the National Institutes of Health (FNIH) has named Katherine J. Wu, PhD, a staff writer with The Atlantic, as the recipient of the inaugural Kovler Prize for Trust in Life Science Journalism. Dr. Wu is known for her authoritative and insightful reporting on COVID-19. She also has written extensively on science and health topics for several leading media outlets.

A new study, developed and launched by the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium, found some blood tests are accurate enough that they are suitable for clinical use and could replace spinal taps and brain scans in many patients with cognitive impairment. The study compared the accuracy of leading commercial blood tests in detecting amyloid plaques, a characteristic feature of Alzheimer’s.

The Foundation for the National Institutes of Health (FNIH) has awarded its seventh annual Trailblazer Prize for Clinician-Scientists to Vijay G. Sankaran, MD, PhD, of Boston Children’s Hospital and Harvard Medical School. Dr. Sankaran and his team have made significant advances in the understanding of human blood cell development in health and diseases, including sickle cell anemia, cancer, and rare blood disorders.

The Foundation for the National Institutes of Health (FNIH) announces a new public-private partnership that aims to better differentiate Parkinson’s disease from related neurodegenerative disorders, such as multiple system atrophy, Lewy body dementia, and progressive supranuclear palsy, to enable earlier diagnoses, more timely interventions, and better outcomes.

The Foundation for the National Institutes of Health (FNIH) will award the 2024 Charles A. Sanders, MD, Partnership Award to the National Institutes of Health’s (NIH) National Institute of Neurological Disorders and Stroke (NINDS), AbbVie, and Robert and Sarah Newcomb. The Partnership Award recognizes persons or organizations that have made significant contributions to the FNIH’s work in support of the mission of the NIH.

The Foundation for the National Institutes of Health (FNIH) announces two additions to the FNIH Board of Directors: James W. Down, former Vice Chairman of Mercer Management Consulting, and Perry Steiner, Chairman and CEO of Xactus. The new directors bring deep experience in corporate strategy and operations, entrepreneurial ventures, and executive leadership.

The Foundation for the National Institutes of Health (FNIH) announces the launch of a public-private partnership to build the largest data source for amyotrophic lateral sclerosis (ALS) and expedite the identification of biomarkers and clinical outcome assessments that would allow earlier diagnosis and accelerated drug development for people living with the disease. ALS is a progressive and ultimately fatal neurological disease with few treatment options and no cure yet.

The Foundation for the National Institutes of Health (FNIH) announces two new additions to the FNIH Board of Directors, Nina Kjellson, General Partner at Canaan, and Charles Reinhart III, Chief Financial Officer at Pacira BioSciences, Inc. The new directors bring decades of collective expertise and entrepreneurship in finance, biopharma, and digital health to the Board.

The Foundation for the National Institutes of Health (FNIH) has named the National Institutes of Health’s Eunice Kennedy Shriver National Institute of Child Health and Human Development, GSK, and the O’Neill Family as recipients of the 2023 Charles A. Sanders, M.D., Partnership Award. The Partnership Award recognizes persons or organizations that have made significant contributions to the FNIH’s work in support of the mission of the National Institutes of Health (NIH).

The Foundation for the National Institutes of Health (FNIH) today announces study findings, published in Nature Medicine, demonstrating the effectiveness of noninvasive blood tests to diagnose nonalcoholic steatohepatitis (NASH).1 The results are a significant milestone on the path to regulatory approval by the U.S. Food and Drug Administration (FDA). The findings came from the FNIH’s Biomarkers Consortium, which leads cross-sector efforts to validate and qualify biomarkers that accelerate the development of new therapeutics and health technologies.

The Foundation for the National Institutes of Health (FNIH) is proud to announce two new additions to the FNIH Board of Directors, Dr. Jay Bradner and Jim Weiss. The new directors bring decades of experience and entrepreneurship in life sciences.

Today, the Foundation for the National Institutes of Health (FNIH) announces the Accelerating Medicines Partnership® Bespoke Gene Therapy Consortium (AMP® BGTC) has selected eight rare diseases for its clinical trial portfolio. This portfolio pioneers a novel approach to gene therapy development for rare diseases by demonstrating that manufacturing and testing standards can provide a streamlined approval pathway for first-in-human clinical trials. The announcement comes during the first day of the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting in Los Angeles.

The Foundation for the National Institutes of Health (FNIH) announces that the Type 2 Diabetes Knowledge Portal (T2DKP) is featured in a Cell Metabolism article published today. The T2DKP is a publicly available source of genetic datasets dedicated to type 2 diabetes and its related traits.